nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2012 | short review

Breast cancer: is there a need for biopsy of metastases?

verfasst von: Flora Zagouri, MD, PhD, Martin Filipits, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Hormone receptors and the human epidermal growth factor receptor 2 (HER2) are important pharmaceutical targets that affect the survival of patients with metastatic breast cancer. Knowledge of their expression and/or amplification status is crucial for determining the optimal treatment. However, a discordance of hormone and HER2 receptors of primary and metastatic breast cancer has been observed in several studies. Whether discordant cases represent a true biological phenomenon and are due to clonal selection by chemotherapy, targeted anti-estrogen or anti-HER2 therapy or whether they may result from inconsistent measurement is still debated. This review article presents prospective and retrospective studies that have addressed these issues as well as the underlying responsible mechanisms. Finally, it concludes that a biopsy of metastatic disease can be recommended, when safe and easy to perform because treatment options might change for a significant proportion of patients.

Vorheriger Artikel The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer

Nächster Artikel Advanced breast cancer: new imaging techniques for detection of metastases

Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMed

Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74.CrossRefPubMed

Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer. 1983;52(3):479–85.CrossRefPubMed

Spataro V, Price K, Goldhirsch A, et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The international breast cancer study group (formerly Ludwig group). Ann Oncol. 1992;3(9):733–40.PubMed

Li BD, Byskosh A, Molteni A, Duda RB. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol. 1994;57(2):71–7.CrossRefPubMed

Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14(9):2584–9.PubMed

Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol. 2005;12(1):10–9.CrossRefPubMed

Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat. 2005;90(1):65–70.CrossRefPubMed

Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist. 2008;13(8):838–44.CrossRefPubMed

10.

Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953–8.CrossRefPubMed

11.

Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20(9):1499–504.CrossRefPubMed

12.

Amir E, Clemons M, Freedman OC, et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol. 2010;28:15s (abstr 1007).

13.

Karlsson E, Lindström LS, Wilking U, et al. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol. 2010;28:15s (abstr 1009).

14.

Locatelli MA, Curigliano G, Fumagalli L, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol. 2010;28:18s (abstr 1008).

15.

Botteri E, Disalvatore D, Curigliano G, et al. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast. 2011. http://dx.doi.org/10.1016/j.breast. Accessed 14 Dec 2011.

16.

Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res. 2001;61(14):5345–8.PubMed

17.

Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13(7):1036–43.CrossRefPubMed

18.

Vincent-Salomon A, Jouve M, Genin P, et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer. 2002;94(8):2169–73.CrossRefPubMed

19.

Edgerton SM, Moore D 2nd, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol. 2003;11(3):214–21.PubMed

20.

Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol. 2004;203(4):918–26.CrossRefPubMed

21.

Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005;103(9):1763–9.CrossRefPubMed

22.

Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93(5):552–6.CrossRefPubMed

23.

Vincent-Salomon A, Pierga JY, Couturier J, et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer. 2007;96(4):654–9.CrossRefPubMed

24.

Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer. 2008;122(5):999–1004.CrossRefPubMed

25.

Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat. 2009;113(2):301–6.CrossRefPubMed

26.

Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(6):593–9.

27.

Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464(7291):999–1005.CrossRefPubMed

28.

Tortola S, Steinert R, Hantschick M, et al. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol. 2001;19(11):2837–43.PubMed

29.

Schmid K, Oehl N, Wrba F, et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009;15(14):4554–60.CrossRefPubMed

Titel: Breast cancer: is there a need for biopsy of metastases?
verfasst von: Flora Zagouri, MD, PhD
Martin Filipits, PhD
Publikationsdatum: 01.06.2012
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-012-0005-4

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Cellular immunotherapy for cancer. Past, present, future

Interventional therapy for symptomatic bronchial carcinoma

Surgical removal of the primary?—The role it plays in stage IV breast cancer

Recent advances and future challenges in the treatment of upper gastrointestinal malignancies

Breast cancer—advanced stage: “cure—still a long way to go?”

The role of biomarkers in the choice of therapy in breast cancer